Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 56

Cited In for PubMed (Select 17638856)

1.

Survivin-specific T cell receptor targets tumor but not T cells.

Arber C, Feng X, Abhyankar H, Romero E, Wu MF, Heslop HE, Barth P, Dotti G, Savoldo B.

J Clin Invest. 2015 Jan;125(1):157-68. doi: 10.1172/JCI75876. Epub 2014 Nov 21.

2.

Genome editing in mouse spermatogonial stem/progenitor cells using engineered nucleases.

Fanslow DA, Wirt SE, Barker JC, Connelly JP, Porteus MH, Dann CT.

PLoS One. 2014 Nov 19;9(11):e112652. doi: 10.1371/journal.pone.0112652. eCollection 2014.

3.

The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells.

Gargett T, Brown MP.

Front Pharmacol. 2014 Oct 28;5:235. doi: 10.3389/fphar.2014.00235. eCollection 2014. Review.

4.

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.

Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G.

Blood. 2014 Jun 19;123(25):3895-905. doi: 10.1182/blood-2014-01-551671. Epub 2014 Apr 21.

5.

CAR T cells for solid tumors: armed and ready to go?

Kakarla S, Gottschalk S.

Cancer J. 2014 Mar-Apr;20(2):151-5. doi: 10.1097/PPO.0000000000000032. Review.

6.

Genetically modified T cells to target glioblastoma.

Krebs S, Rodríguez-Cruz TG, Derenzo C, Gottschalk S.

Front Oncol. 2013 Dec 31;3:322. doi: 10.3389/fonc.2013.00322. Review.

7.

Design and development of therapies using chimeric antigen receptor-expressing T cells.

Dotti G, Gottschalk S, Savoldo B, Brenner MK.

Immunol Rev. 2014 Jan;257(1):107-26. doi: 10.1111/imr.12131. Review.

8.

Engineered T cells for cancer treatment.

Anurathapan U, Leen AM, Brenner MK, Vera JF.

Cytotherapy. 2014 Jun;16(6):713-33. doi: 10.1016/j.jcyt.2013.10.002. Epub 2013 Nov 13. Review.

9.

Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.

Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, Dotti G.

Clin Cancer Res. 2014 Jan 1;20(1):131-9. doi: 10.1158/1078-0432.CCR-13-1016. Epub 2013 Oct 4. Erratum in: Clin Cancer Res. 2014 Aug 15;20(16):4413.

10.

Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Yvon E, Ahmed N.

Mol Ther. 2013 Nov;21(11):2087-101. doi: 10.1038/mt.2013.185. Epub 2013 Aug 13. Erratum in: Mol Ther. 2014 May;22(5):1063. Gottachalk, Stephen [corrected to Gottschalk, Stephen].

11.

The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.

Arber C, Abhyankar H, Heslop HE, Brenner MK, Liu H, Dotti G, Savoldo B.

Gene Ther. 2013 Sep;20(9):958-62. doi: 10.1038/gt.2013.25. Epub 2013 May 23.

12.

Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery.

Fu X, Rivera A, Tao L, Zhang X.

Int J Cancer. 2013 Nov 15;133(10):2483-92. doi: 10.1002/ijc.28269. Epub 2013 Jul 11.

13.

The basic principles of chimeric antigen receptor design.

Sadelain M, Brentjens R, Rivière I.

Cancer Discov. 2013 Apr;3(4):388-98. doi: 10.1158/2159-8290.CD-12-0548. Epub 2013 Apr 2. Review.

14.

Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.

Maher J.

ISRN Oncol. 2012;2012:278093. doi: 10.5402/2012/278093. Epub 2012 Dec 9.

15.

Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.

Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, Savoldo B.

Clin Cancer Res. 2013 Jan 1;19(1):106-17. doi: 10.1158/1078-0432.CCR-12-2143. Epub 2012 Nov 13.

16.

Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.

Hoyos V, Savoldo B, Dotti G.

Haematologica. 2012 Nov;97(11):1622-31. doi: 10.3324/haematol.2012.064303. Epub 2012 Aug 28. Review.

17.

Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Nagasawa DT, Fong C, Yew A, Spasic M, Garcia HM, Kruse CA, Yang I.

Neurosurg Clin N Am. 2012 Jul;23(3):481-95. doi: 10.1016/j.nec.2012.04.008. Review.

18.

IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.

Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, Guo L, Heczey A, Asgharzadeh S, Kim E, Dotti G, Metelitsa LS.

J Clin Invest. 2012 Jun;122(6):2221-33. doi: 10.1172/JCI59535. Epub 2012 May 8.

19.

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia.

Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E, Finney H, Lawson A, Brenner M, Biondi A, Biagi E, Rousseau R.

Adv Hematol. 2012;2012:683065. doi: 10.1155/2012/683065. Epub 2012 Jan 5.

20.

Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.

Wu C, Dunbar CE.

Front Med. 2011 Dec;5(4):356-71. doi: 10.1007/s11684-011-0159-1. Epub 2011 Dec 27. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk